Free Trial
NASDAQ:CLBT

Cellebrite DI (CLBT) Stock Price, News & Analysis

$13.98
+0.28 (+2.04%)
(As of 07/26/2024 ET)
Today's Range
$13.84
$14.05
50-Day Range
$10.41
$13.98
52-Week Range
$6.36
$14.05
Volume
1.60 million shs
Average Volume
1.07 million shs
Market Capitalization
$2.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.17

Cellebrite DI MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5.8% Downside
$13.17 Price Target
Short Interest
Healthy
3.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of Cellebrite DI in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
23.53%
From $0.34 to $0.42 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Business Services Sector

251st out of 317 stocks

Prepackaged Software Industry

171st out of 202 stocks

CLBT stock logo

About Cellebrite DI Stock (NASDAQ:CLBT)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft. It provides Inseyets, a digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations. The company's digital forensics software also offers data extraction, decoding capabilities, workflows, and automation capabilities. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence by automating data analysis and visualization; Smart Search, an open source intelligence tool that automates the collection and review of publicly available online data; and Guardian, a case and evidence management solution. Further, the company offers digital forensic software for enterprises and service providers, including Inseyets for Enterprise, Endpoint Inspector, and Mobile Now; and professional services, such as training and certification services, and other services. It serves federal and state and local agencies. The company was incorporated in 1999 and is headquartered in Petah Tikva, Israel.

CLBT Stock Price History

CLBT Stock News Headlines

We just added a $300 account credit to your MarketBeat subscription
MarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.
We’re in a code red crisis and 99% of Americans are clueless
Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES!
Cellebrite DI Ltd. (CLBTW)
Cellebrite Announces First-Quarter 2024 Results
Cellebrite Q1 2024 Earnings Preview
See More Headlines
Receive CLBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellebrite DI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/23/2024
Today
7/26/2024
Next Earnings (Confirmed)
8/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
Computer Software
Current Symbol
NASDAQ:CLBT
Employees
1,008
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.17
High Stock Price Target
$16.00
Low Stock Price Target
$9.00
Potential Upside/Downside
-5.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-81,100,000.00
Pretax Margin
-30.94%

Debt

Sales & Book Value

Annual Sales
$325.11 million
Cash Flow
$0.28 per share
Book Value
$0.18 per share

Miscellaneous

Free Float
194,194,000
Market Cap
$2.88 billion
Optionable
Optionable
Beta
1.50
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Yossi Carmil (Age 56)
    Founder, CEO & Director
    Comp: $1.14M
  • Ms. Dana Gerner (Age 57)
    Chief Financial Officer
    Comp: $649k
  • Mr. Ronnen Armon (Age 61)
    Chief Products & Technologies Officer
    Comp: $516k
  • Ms. Lisa Cole (Age 49)
    Chief Marketing Officer
    Comp: $499k
  • Mr. Leeor Ben-Peretz (Age 48)
    Chief Strategy Officer
    Comp: $470k
  • Mr. Thomas E. Hogan (Age 65)
    Executive Chairman
  • Mr. Arnon Zilberman
    Executive Vice President of Information Systems & Operations
  • Andrew Kramer
    Vice President of Investor Relations
  • Ms. Ayala Berler Shapira (Age 53)
    General Counsel & Chief Compliance Officer
  • Ms. Zohar Tadmor-Eilat (Age 53)
    Chief People Officer

CLBT Stock Analysis - Frequently Asked Questions

How have CLBT shares performed this year?

Cellebrite DI's stock was trading at $8.66 at the beginning of the year. Since then, CLBT stock has increased by 61.4% and is now trading at $13.9750.
View the best growth stocks for 2024 here
.

How were Cellebrite DI's earnings last quarter?

Cellebrite DI Ltd. (NASDAQ:CLBT) released its quarterly earnings data on Thursday, May, 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Cellebrite DI's revenue was up 25.8% on a year-over-year basis.

Who are Cellebrite DI's major shareholders?

Cellebrite DI's top institutional investors include ARK Investment Management LLC (0.10%), Harbor Capital Advisors Inc. (0.02%), Juncture Wealth Strategies LLC (0.02%) and Hennessy Advisors Inc. (0.01%).

How do I buy shares of Cellebrite DI?

Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLBT) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners